Adverse effects of androgen deprivation therapy in prostate cancer

Current management issues

Aditya Bagrodia, Christopher DiBlasio, Robert Wake, Ithaar Derweesh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Prostate cancer (CaP) is the most common visceral malignancy and a leading cause of cancer death in men. Androgen deprivation therapy (ADT) is an established treatment for locally advanced and metastatic CaP, and often used as primary therapy in select patients. As ADT has continued to assume an important role in the treatment of CaP, a greater appreciation of potential adverse effects has been acknowledged in men receiving this therapy. Given that all treatments for CaP are frequently associated with some degree of morbidity and can have a negative impact on health-related quality of life (HRQOL), the potential benefits of any treatment, including ADT, must outweigh the risks, particularly in patients with asymptomatic disease. Once the choice to proceed with ADT is complete, it is imperative for the urologist to possess comprehensive knowledge of the potential adverse effects of ADT. This permits the urologist to properly monitor for, perhaps diminish, and to treat any linked morbidities. Patient complaints related to ADT such as a decrease in HRQOL, cognitive and sexual dysfunction, hot flashes, endocrine abnormalities, cardiovascular disease, and alterations in skeletal and body composition are commonly reported throughout the literature. Herein, we review the principal adverse effects linked with ADT in CaP patients and suggest various universal strategies that may diminish these potential adverse consequences associated with this therapy.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalIndian Journal of Urology
Volume25
Issue number2
DOIs
StatePublished - Jul 1 2009

Fingerprint

Androgens
Prostatic Neoplasms
Therapeutics
Quality of Life
Hot Flashes
Morbidity
Asymptomatic Diseases
Body Composition
Cause of Death
Neoplasms
Cardiovascular Diseases

Keywords

  • Androgen deprivation therapy
  • Complications
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Adverse effects of androgen deprivation therapy in prostate cancer : Current management issues. / Bagrodia, Aditya; DiBlasio, Christopher; Wake, Robert; Derweesh, Ithaar.

In: Indian Journal of Urology, Vol. 25, No. 2, 01.07.2009, p. 169-176.

Research output: Contribution to journalArticle

Bagrodia, Aditya ; DiBlasio, Christopher ; Wake, Robert ; Derweesh, Ithaar. / Adverse effects of androgen deprivation therapy in prostate cancer : Current management issues. In: Indian Journal of Urology. 2009 ; Vol. 25, No. 2. pp. 169-176.
@article{9df6c7121448441fa3440e4ee4e8b33b,
title = "Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues",
abstract = "Prostate cancer (CaP) is the most common visceral malignancy and a leading cause of cancer death in men. Androgen deprivation therapy (ADT) is an established treatment for locally advanced and metastatic CaP, and often used as primary therapy in select patients. As ADT has continued to assume an important role in the treatment of CaP, a greater appreciation of potential adverse effects has been acknowledged in men receiving this therapy. Given that all treatments for CaP are frequently associated with some degree of morbidity and can have a negative impact on health-related quality of life (HRQOL), the potential benefits of any treatment, including ADT, must outweigh the risks, particularly in patients with asymptomatic disease. Once the choice to proceed with ADT is complete, it is imperative for the urologist to possess comprehensive knowledge of the potential adverse effects of ADT. This permits the urologist to properly monitor for, perhaps diminish, and to treat any linked morbidities. Patient complaints related to ADT such as a decrease in HRQOL, cognitive and sexual dysfunction, hot flashes, endocrine abnormalities, cardiovascular disease, and alterations in skeletal and body composition are commonly reported throughout the literature. Herein, we review the principal adverse effects linked with ADT in CaP patients and suggest various universal strategies that may diminish these potential adverse consequences associated with this therapy.",
keywords = "Androgen deprivation therapy, Complications, Prostate cancer",
author = "Aditya Bagrodia and Christopher DiBlasio and Robert Wake and Ithaar Derweesh",
year = "2009",
month = "7",
day = "1",
doi = "10.4103/0970-1591.52907",
language = "English (US)",
volume = "25",
pages = "169--176",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Adverse effects of androgen deprivation therapy in prostate cancer

T2 - Current management issues

AU - Bagrodia, Aditya

AU - DiBlasio, Christopher

AU - Wake, Robert

AU - Derweesh, Ithaar

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Prostate cancer (CaP) is the most common visceral malignancy and a leading cause of cancer death in men. Androgen deprivation therapy (ADT) is an established treatment for locally advanced and metastatic CaP, and often used as primary therapy in select patients. As ADT has continued to assume an important role in the treatment of CaP, a greater appreciation of potential adverse effects has been acknowledged in men receiving this therapy. Given that all treatments for CaP are frequently associated with some degree of morbidity and can have a negative impact on health-related quality of life (HRQOL), the potential benefits of any treatment, including ADT, must outweigh the risks, particularly in patients with asymptomatic disease. Once the choice to proceed with ADT is complete, it is imperative for the urologist to possess comprehensive knowledge of the potential adverse effects of ADT. This permits the urologist to properly monitor for, perhaps diminish, and to treat any linked morbidities. Patient complaints related to ADT such as a decrease in HRQOL, cognitive and sexual dysfunction, hot flashes, endocrine abnormalities, cardiovascular disease, and alterations in skeletal and body composition are commonly reported throughout the literature. Herein, we review the principal adverse effects linked with ADT in CaP patients and suggest various universal strategies that may diminish these potential adverse consequences associated with this therapy.

AB - Prostate cancer (CaP) is the most common visceral malignancy and a leading cause of cancer death in men. Androgen deprivation therapy (ADT) is an established treatment for locally advanced and metastatic CaP, and often used as primary therapy in select patients. As ADT has continued to assume an important role in the treatment of CaP, a greater appreciation of potential adverse effects has been acknowledged in men receiving this therapy. Given that all treatments for CaP are frequently associated with some degree of morbidity and can have a negative impact on health-related quality of life (HRQOL), the potential benefits of any treatment, including ADT, must outweigh the risks, particularly in patients with asymptomatic disease. Once the choice to proceed with ADT is complete, it is imperative for the urologist to possess comprehensive knowledge of the potential adverse effects of ADT. This permits the urologist to properly monitor for, perhaps diminish, and to treat any linked morbidities. Patient complaints related to ADT such as a decrease in HRQOL, cognitive and sexual dysfunction, hot flashes, endocrine abnormalities, cardiovascular disease, and alterations in skeletal and body composition are commonly reported throughout the literature. Herein, we review the principal adverse effects linked with ADT in CaP patients and suggest various universal strategies that may diminish these potential adverse consequences associated with this therapy.

KW - Androgen deprivation therapy

KW - Complications

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=67651238522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651238522&partnerID=8YFLogxK

U2 - 10.4103/0970-1591.52907

DO - 10.4103/0970-1591.52907

M3 - Article

VL - 25

SP - 169

EP - 176

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 2

ER -